Sano Medical Science and Technology Co., Ltd. is an international company rooted in China, facing the global market, focusing on the research and development, production and sales of medical devices.

The company was founded in Tianjin Economic and Technological Development Zone in 2007 with a registered capital of RMB 410 million and has subsidiaries in Beijing, Suzhou, Hong Kong, the United States, Japan and France. In October 2019, the company landed on the Shanghai Stock Exchange and became a listed company on the Science and Technology Innovation Board (stock code 688108.SH).

After more than ten years of development, Sano Medical has established an internationally-level R&D, production and operation system, covering key areas of interventional treatment such as cardiovascular, cerebrovascular, and structural heart disease. The company continues to focus on product innovation and quickly enriches product pipeline layout. It currently has 8 key technologies and 19 products on the market; it has more than 200 patents worldwide, covering mainstream countries and regions such as China, the United States, and Europe; the company The results of product clinical research have been conducted in 31 papers of various types in domestic and international core journals (including 18 international core journals); they have undertaken 7 national and provincial scientific research projects, including the "13th Five-Year Plan" National Key R&D Programme.

Since its establishment, the company's main products, coronary drug stents, coronary balloons, intracranial rapid exchange balloons, intracranial drug elution stents, etc., have been used in more than 1.9 million, and have entered more than 3,000 hospitals and hundreds of thousands of patients around the world. Therefore, benefits. HT Supreme is a cardiac stent product that has conducted pre-marketing clinical research in China, the United States, Japan and Europe in my country and applied for product patents in the aforementioned countries and regions. At present, the product has obtained the EU CE certification and the domestic "Medical Device Registration Certificate", and officially submitted an approval application to the US Food and Drug Administration FDA in December 2021. The new generation of HT series stents have been shortlisted for the national renewal of coronary stents, and have been selected by more than a thousand hospitals across the country, providing doctors with richer clinical solutions, and more patients will benefit from international quality innovative interventional products.

Sano Medical adheres to independent innovation, adheres to quality, and takes the international path. It is committed to creating high-quality and inclusive medical products, improving the influence of "China Creation" on an international scale, and creating greater value for society.